166 related articles for article (PubMed ID: 23810006)
1. Targeting progesterone receptors in breast cancer.
Giulianelli S; Molinolo A; Lanari C
Vitam Horm; 2013; 93():161-84. PubMed ID: 23810006
[TBL] [Abstract][Full Text] [Related]
2. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and mechanism of action of Proellex, an antiprogestin in aromatase overexpressing and Letrozole resistant T47D breast cancer cells.
Gupta A; Mehta R; Alimirah F; Peng X; Murillo G; Wiehle R; Mehta RG
J Steroid Biochem Mol Biol; 2013 Jan; 133():30-42. PubMed ID: 22939887
[TBL] [Abstract][Full Text] [Related]
4. Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways.
Carnevale RP; Proietti CJ; Salatino M; Urtreger A; Peluffo G; Edwards DP; Boonyaratanakornkit V; Charreau EH; Bal de Kier Joffé E; Schillaci R; Elizalde PV
Mol Endocrinol; 2007 Jun; 21(6):1335-58. PubMed ID: 17440047
[TBL] [Abstract][Full Text] [Related]
5. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness.
Rojas PA; May M; Sequeira GR; Elia A; Alvarez M; Martínez P; Gonzalez P; Hewitt S; He X; Perou CM; Molinolo A; Gibbons L; Abba MC; Gass H; Lanari C
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376177
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in structure of progestins and their binding to progesterone receptors.
Cabeza M; Heuze Y; Sánchez A; Garrido M; Bratoeff E
J Enzyme Inhib Med Chem; 2015 Feb; 30(1):152-9. PubMed ID: 24666307
[TBL] [Abstract][Full Text] [Related]
7. An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity.
Wei LL; Hawkins P; Baker C; Norris B; Sheridan PL; Quinn PG
Mol Endocrinol; 1996 Nov; 10(11):1379-87. PubMed ID: 8923464
[TBL] [Abstract][Full Text] [Related]
8. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
9. Sex hormone receptors in breast cancer.
D'Abreo N; Hindenburg AA
Vitam Horm; 2013; 93():99-133. PubMed ID: 23810004
[TBL] [Abstract][Full Text] [Related]
10. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
[TBL] [Abstract][Full Text] [Related]
11. Effects of estradiol and progestogens on human breast cells: regulation of sex steroid receptors.
Chen FP; Chien MH; Chen HY; Huang TS; Ng YT
Taiwan J Obstet Gynecol; 2013 Sep; 52(3):365-73. PubMed ID: 24075375
[TBL] [Abstract][Full Text] [Related]
12. Ligand- and cell-specific effects of signal transduction pathway inhibitors on progestin-induced vascular endothelial growth factor levels in human breast cancer cells.
Wu J; Brandt S; Hyder SM
Mol Endocrinol; 2005 Feb; 19(2):312-26. PubMed ID: 15528272
[TBL] [Abstract][Full Text] [Related]
13. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
14. Effect of overexpression of progesterone receptor A on endogenous progestin-sensitive endpoints in breast cancer cells.
McGowan EM; Clarke CL
Mol Endocrinol; 1999 Oct; 13(10):1657-71. PubMed ID: 10517668
[TBL] [Abstract][Full Text] [Related]
15. Estrogen-mediated mechanisms to control the growth and apoptosis of breast cancer cells: a translational research success story.
McDaniel RE; Maximov PY; Jordan VC
Vitam Horm; 2013; 93():1-49. PubMed ID: 23810002
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
17. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
18. Tracking progesterone receptor-mediated actions in breast cancer.
Knutson TP; Lange CA
Pharmacol Ther; 2014 Apr; 142(1):114-25. PubMed ID: 24291072
[TBL] [Abstract][Full Text] [Related]
19. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Wargon V; Riggio M; Giulianelli S; Sequeira GR; Rojas P; May M; Polo ML; Gorostiaga MA; Jacobsen B; Molinolo A; Novaro V; Lanari C
Int J Cancer; 2015 Jun; 136(11):2680-92. PubMed ID: 25363551
[TBL] [Abstract][Full Text] [Related]
20. [Biomarkers of endocrine therapy-resistance in breast cancers].
de Cremoux P; Debled M; Bonnefoi H; Cottu P
Bull Cancer; 2010 Aug; 97(8):951-63. PubMed ID: 20605764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]